By Anthony O. Goriainoff

 

AstraZeneca PLC said Tuesday that its supplemental new drug application, or sNDA, for its cancer treatment, Lynparza in combination with abiraterone, has been granted a priority review by the U.S. Food and Drug Administration.

The Anglo-Swedish pharma giant said the priority review is for the treatment of adult patients with metastatic castration-resistant prostate cancer.

The U.S. Food and Drug Administration grants priority review status to medicinal applications that, if approved, would offer significant improvements over available options.

AstraZeneca said the sNDA was based on results from the PROpel Phase 3 trial, which showed that Lynparza, when combined with abiraterone, reduced the risk of disease progression or death by 34% versus abiraterone alone.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

August 16, 2022 02:35 ET (06:35 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Ago 2022 a Set 2022 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Set 2021 a Set 2022 Clicca qui per i Grafici di Astrazeneca